• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $FLXN

    Flexion Therapeutics, Inc.

    Subscribe to $FLXN
    $FLXN
    Major Pharmaceuticals
    Health Care

    Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.

    IPO Year: 2014

    Exchange: NASDAQ

    Website: flexiontherapeutics.com

    Peers

    $TCDA

    Recent Analyst Ratings for Flexion Therapeutics, Inc.

    DatePrice TargetRatingAnalyst
    11/19/2021Outperform → Market Perform
    Northland Capital Markets
    10/19/2021$25.00 → $10.00Buy → Neutral
    HC Wainwright & Co.
    10/12/2021$20.00 → $12.00Outperform → Market Perform
    BMO Capital
    10/12/2021Strong Buy → Market Perform
    Raymond James
    10/12/2021$14.00 → $10.00Outperform → Neutral
    Credit Suisse
    8/6/2021$8.00 → $6.00Neutral
    Goldman Sachs
    8/5/2021$20.00 → $18.00Buy
    Needham
    See more ratings